title: Similar weight-adjusted insulin secretion and insulin sensitivity in short-duration late autoimmune diabetes of adulthood (LADA) and type 2 diabetes: Action LADA 9 [corrected].
abstract: OBJECTIVE
  To explore insulin sensitivity and insulin secretion in people with latent autoimmune diabetes in adulthood (LADA) compared with that in people with type 2 diabetes.
  
  
  METHODS
  A total of 12 people with LADA, defined as glutamic acid decarboxylase (GAD) antibody positivity and > 1 year of insulin independency (group A) were age-matched pairwise to people with type 2 diabetes (group B) and to six people with type 2 diabetes of similar age and BMI (group C). β-Cell function (first-phase insulin secretion and assessment of insulin pulsatility), insulin sensitivity (hyperinsulinemic-euglycemic clamp) and metabolic response during a mixed meal were studied.
  
  
  RESULTS
  Both first-phase insulin secretion and insulin release during the meal were greater (P = 0.05 and P = 0.009, respectively) in type 2 diabetes as compared with LADA; these differences were lost on adjustment for BMI (group C) and could be explained by BMI alone in a multivariate analysis. Neither insulin pulsatility, incretin secretion nor insulin sensitivity differed among the groups.
  
  
  CONCLUSIONS
  We found no evidence that LADA and type 2 diabetes were distinct disease entities beyond the differences explained by BMI.
authors.affiliation: Sydvestjysk Hospital, Esbjerg, Denmark; Odense University Hospital, Odense, Denmark.
authors.forename: C B
authors.initials: CB
authors.lastname: Juhl
authors.forename: U
authors.initials: U
authors.lastname: Bradley
authors.forename: J J
authors.initials: JJ
authors.lastname: Holst
authors.forename: R D
authors.initials: RD
authors.lastname: Leslie
authors.forename: K B
authors.initials: KB
authors.lastname: Yderstraede
authors.forename: S
authors.initials: S
authors.lastname: Hunter
mesh_terms: D000328:Adult; D017668:Age of Onset; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism*; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000378:metabolism*; D015309:Glucose Clamp Technique; D005968:Glutamate Decarboxylase / Q000037:antagonists & inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D054795:Incretins / Q000097:blood / Q000378:metabolism; D007328:Insulin / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D007333:Insulin Resistance; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism*; D016555:Matched-Pair Analysis; D009765:Obesity / Q000150:complications; D050177:Overweight / Q000150:complications; D019518:Postprandial Period
chemical_list: D001323:Autoantibodies; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D054795:Incretins; D007328:Insulin; D005968:Glutamate Decarboxylase